<DOC>
	<DOCNO>NCT01923805</DOCNO>
	<brief_summary>This prospective study evaluate effectiveness Vitagel ( VG ) reduce blood loss associate Revision Total Knee Arthroplasty ( RTKA ) procedures assess patient 's change hemoglobin/hematocrit . Transfusion rate use VG compare current standard care also evaluate . The effectiveness VG potentially reduce pain , increase return function quality life assess modified Knee Injury Osteoarthritis Outcome Score ( Modified KOOS ) , Numerical Assessment Pain Scale ( NAPS ) , SF-12 health survey . Analgesic use record post-operatively .</brief_summary>
	<brief_title>Vitagel Revision Total Knee Arthroplasty</brief_title>
	<detailed_description>This prospective , randomize , blind clinical trial involve 4 orthopedic surgeon perform Revision Total Knee Arthroplasty ( RTKA ) , include Trevor Murray ( PI ) , Viktor Krebs , Robert Molloy , Carlos Higuera . A total eighty subject schedule RTKA , meet inclusion criterion exhibit none exclusion criterion invite participate study . Only subject sign Institutional Review Board-approved Informed Consent Form enter Study . In forty treatment Subjects , VG apply surgical site . The forty control subject receive surgeon 's standard care , without use hemostatic agent . The subject inform assignment , research investigator make determination blood transfusion requirement study subject also blind subject assign arm study . The research investigator perform RTKA remain blind study arm randomization envelope open , take place surgery , hemostasis achieve use bovie electrocautery , prior closure knee capsule . Assessments make per Time Events Schedule . Subjects evaluate intra- post-operative complication , event , occur , record course study . Details describe event , cause event , treatment resolution document .</detailed_description>
	<criteria>Patients must meet follow criterion order consider appropriate candidate participation study : 1 . Is schedule RTKA ( may second stage/reimplantation twostage revision infection ) ; 2 . Is able willing provide voluntary write informed consent participation study able comply protocol requirement ; 3 . Is ages 18 85 time surgery . Both male female include ; 4 . Is physically mentally willing able comply clinical evaluation followup schedule ; The following exclusion criterion address safety followup concern contraindication could confound study . If patient exhibit one follow criterion , patient eligible participate study : 1 . Is know sensitive material bovine origin ; 2 . Is undergoing bilateral RTKA ; 3 . Is undergo single component revision ( i.e . tibial femoral component ) 4 . Is undergoing polyethylene revision 5 . Is predonating autologous blood ; 6 . Have preoperative platelet count less 100,000 7 . Have previous history venous thromboembolism deep vein thrombosis ; 8 . Have medical condition require anticoagulation 9 . Currently use Coumadin ; 10 . Have history Heparin induce thrombocytopenia Lovenox induce thrombocytopenia ; 11 . Have history rheumatoid arthritis inflammatory arthritis ; 12 . Have peripheral vascular disease ; 13 . Have evidence bleeding metabolicbased hemolytic disorder ( hemophilia anticoagulation use ) , hypercoaguable disorder ; 14 . Have history liver disease . Patients liver dysfunction cirrhosis hepatitis may impair production factor clot cascade may make individual prone bleed , especially use anticoagulant . For reason , patient also exclude study baseline INR great 1.3 APTT great 32.4 ; 15 . Have history fail treatment abuse , actively abuse , illegal drug , solvent , alcohol ; 16 . Have systemic infection infection site surgery ; 17 . Is prisoner ; 18 . Is pregnant nursing ; 19 . Have condition deem physician medical staff nonconducive patient 's ability complete study , potential risk patient 's health wellbeing . Exclusion Criteria ( Intraoperative ) 1 . Clinical evidence cancer and/or infection surgical site 2 . Use procedure approve unapproved product purpose hemostasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>